FPR1 expression was also reported in breast cancer [197,198] and it can be activated, in an autocrine manner, by the N-terminal peptide of AnxA1, which is secreted by the triple-negative breast cancer cell line, MDA-MB-231. Here, ANXA1 is linked to triple-negative breast carcinoma.